A two-stage Bayesian design for co-development of new drugs and companion diagnostics

Statistics in Medicine

Volumn 31, Issue 10, 2012, Pages 901-914

  Karuri, Stella Wanjugu ^a   Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bayesian inference; Clinical trials design; Predictive biomarkers; Prior distribution; Type I error probabilities

Indexed keywords

BIOLOGICAL MARKER;

ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; CLINICAL STUDY; DIAGNOSTIC PROCEDURE; DRUG DESIGN; DRUG RESEARCH; HEALTH STATISTICS; MATHEMATICAL COMPUTING; PATIENT SAFETY; PREDICTION; PREVALENCE; PROBABILITY; STUDY DESIGN; THERAPY EFFECT;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG DISCOVERY; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859721881     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4462     Document Type: Article

References (21)

1. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opinion in Medical Diagnostics 2008; 2:721-729.
2. Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Communications in Statistics - Theory and Methods 1994; 23(2):499-531. DOI: 10.1080/03610929408831269.
3. Maitournam A, Simon R. On the efficency of targeted clinical trials. Statistics in Medicine 2005; 24:329-339. DOI: 10.1002/sim.1975.
4. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2004; 10:6759-6763. DOI: 10.1158/1078-0432.CCR-04-0496.
5. Simon R. The use of genomics in clinical trial design. Clinical Cancer Research 2008; 14:5984-5993. DOI: 10.1158/1078-0432.CCR-07-4531.
6. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. Journal of Clinical Oncology 2005; 23(9):2020-2027. DOI: 10.1200/JCO.2005.01.112.
7. Wang S, O'Neill RT, Hung JMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6:227-244. DOI: 10.1002/pst.300.
8. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005; 11:7872-7878.
9. Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: treatment with possible biomarker-defined subset effect. Journal on National Cancer Institute 2007; 99:1036-1043. DOI: 10.1093/jnci/djm022.
10. Berry DA. A case for Bayesianism in clinical trials. Statistics in Medicine 1993; 12:1377-1393. DOI: 10.1002/sim.4780121504.
11. Greenhouse JB, Wasserman L. Robust bayesian methods for monitoring clinical trials. Statistics in Medicine 1995; 14:1379-1391. DOI: 10.1002/sim.4780141210.
12. Chaloner K, Church T, Louis TA, Matts JP. Graphical elicitation of a prior distribution for a clinical trial. The Statistician 1993; 42:341-353.
13. Carlin BP, Sargent DJ. Robust bayesian approaches for clinical trial monitoring. Statistics in Medicine 1996; 15:1093-1106. DOI: 10.1002/(SICI)1097-0258(19960615)15:11<1093::AID-SIM231>3.0.CO;2-0.
14. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. Journal of Clinical Oncology 2004; 22(5):777-784. DOI: 10.1200/JCO.2004.08.001.
15. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007; 25(13):1658-1664. DOI: 10.1200/JCO.2006.08.1620.
16. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007; 25(15):1960-1966. DOI: 10.1200/JCO.2006.07.9525.
17. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003; 21(17):3194-3200. DOI: 10.1200/JCO.2003.02.153.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 2005; 353(16):1659-1672. DOI: 10.1056/NEJMoa052306.
19. Schaid DJ, Wieand S, Therneau TM. Optimal two-stage screening designs for survival comparison. Biometrika 1990; 7:507-513.
20. Simon R, Wang S. Use of genomic signatures in therapeutics development in oncology and other diseases. The Pharmacogenomic Journal 2006; 6:166-173.
21. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703. DOI: 10.1002/sim.1362.